



Active substances set

Search phrase: non-Hodgkin lymphoma

Below you will find a list of active substances registered by the European Medical Agency (EMA) in the last 15 years, recommended by the European Society of Clinical Oncology (ESMO) and their reimbursement status in the country.

non-Hodgkin lymphoma

Obinutuzumab in combination with chemotherapy, followed by Obinutuzumab maintenance therapy in patients achieving a response, is indicated for the treatment of patients with previously untreated advanced

FL. Obinutuzumab in combination with bendamustine followed by Obinutuzumab maintenance is indicated for the treatment of patients with FL who did not respond or who progressed during or up to 6 months after treatment with rituximab or a rituximab-containing regimen.

no reimbursement

ESMO

Lisocabtagene

Obinutuzumab

maraleucel

Lisocabtagene maraleucel is indicated for the treatment of adult patients with diffuse large B-cell lymphoma (DLBCL), high grade B-cell lymphoma (HGBCL), primary mediastinal large B-cell lymphoma (PMBCL) and follicular lymphoma grade 3B (FL3B), who relapsed within 12 months from completion of, or are refractory to, first-line chemoimmunotherapy. Lisocabtagene maraleucel is indicated for the treatment of adult patients with relapsed or refractory DLBCL, PMBCL and FL3B, after two or more lines of systemic therapy.

O NO REIMBURSEMENT

ESMO

Loncastuximab

tesirine

Loncastuximab tesirine as monotherapy is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and high-grade Bcell lymphoma (HGBL), after two or more lines of systemic



S ESMO

Glofitamab as monotherapy is indicated for the treatment O REIMBURSEMENT of adult patients with relapsed or refractory diffuse large Glofitamab B-cell lymphoma (DLBCL), after two or more lines of systemic therapy. Zanubrutinib in combination with obinutuzumab is NO REIMBURSEMENT indicated for the treatment of adult patients with Zanubrutinib refractory or relapsed follicular lymphoma (FL) who have **ESMO** received at least two prior systemic therapies. Odronextamab as monotherapy is indicated for the NO REIMBURSEMENT treatment of adult patients with relapsed or refractory **Odronextamab** diffuse large B-cell lymphoma (r/r DLBCL) after two or more lines of systemic therapy. Aacalabrutinib in combination with bendamustine and rituximab (BR) is indicated for the treatment of adult patients with previously untreated mantle cell lymphoma NO REIMBURSEMENT (MCL) who are not eligible for autologous stem cell **Acalabrutinib** transplant (ASCT). Aacalabrutinib as monotherapy is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) not previously treated with a BTK inhibitor. REIMBURSEMENT Ibrutinib as a single agent is indicated for the treatment of WITH RESTRICTIONS adult patients with relapsed or refractory mantle cell **Ibrutinib** lymphoma (MCL). **ESMO** Lenalidomide in combination with rituximab (anti-CD20 antibody) is indicated for the treatment of adult patients REIMBURSEMENT with previously treated follicular lymphoma (Grade 1 -WITH RESTRICTIONS Lenalidomide 3a). Lenalidomide as monotherapy is indicated for the **ESMO** treatment of adult patients with relapsed or refractory mantle cell lymphoma. Axicabtagene ciloleucel is indicated for the treatment of adult patients with diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) that relapses

Axicabtagene ciloleucel

Axicabtagene ciloleucel is indicated for the treatment of adult patients with diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) that relapses within 12 months from completion of, or is refractory to, first-line chemoimmunotherapy. Axicabtagene ciloleucel is indicated for the treatment of adult patients with relapsed or refractory (r/r) DLBCL and primary mediastinal large B-cell lymphoma (PMBCL), after two or more lines of systemic therapy. Axicabtagene ciloleucel is indicated for the treatment of adult patients with r/r follicular lymphoma (FL) after three or more lines of systemic therapy.





Tisagenlecleucel

Tisagenlecleucel is indicated for the treatment of: - Adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. - Adult patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy.

- REIMBURSEMENT
 WITH RESTRICTIONS
- S ESMO

Polatuzumab vedotin

Polatuzumab vedotin in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP) is indicated for the treatment of adult patients with previously untreated diffuse large B-cell lymphoma (DLBCL). Polatuzumab vedotin in combination with bendamustine and rituximab is indicated for the treatment of adult patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) who are not candidates for haematopoietic stem cell transplant.

- REIMBURSEMENT
 WITH RESTRICTIONS
- **ESMO**

Brexucabtagene autoleucel

Mantle cell lymphoma Brexucabtagene autoleucel is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) after two or more lines of systemic therapy including a Bruton's tyrosine kinase (BTK) inhibitor.

- REIMBURSEMENT
 WITH RESTRICTIONS
- **ESMO**

Epcoritamab

Epcoritamab as monotherapy is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. Epcoritamab as monotherapy is indicated for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy.

- REIMBURSEMENT
 WITH RESTRICTIONS
- **ESMO**

Pirtobrutinib

Pirtobrutinib as monotherapy is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) who have been previously treated with a Bruton's tyrosine kinase (BTK) inhibitor.

- REIMBURSEMENT
 WITH RESTRICTIONS
- **ESMO**

Tafasitamab

Tafasitamab is indicated in combination with lenalidomide followed by MINJUVI monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are not eligible for autologous stem cell transplant (ASCT).

- REIMBURSEMENT
- S ESMO

Mosunetuzumab

Mosunetuzumab as monotherapy is indicated for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) who have received at least two prior systemic therapies.



